Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.69 |
| ▸ | F3 | P13726 | 1/20 | 0.69 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.69 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.69 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.69 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.69 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.69 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.69 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adonitol SCHEMBL27591282 | 0.97 | F7 (0.69) | F7F3SARM1SIRT2SIRT6 | |
| Mannitol SCHEMBL21807508 | 0.94 | F7 (0.61) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL21807507 | 0.91 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Demannose SCHEMBL27666893 | 0.91 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL23925306 | 0.89 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL938610 | 0.89 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL28724079 | 0.88 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Xylose SCHEMBL20423632 | 0.88 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL27877775 | 0.87 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Sorbitol SCHEMBL31414236 | 0.86 | ALDH1A1 (0.68) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS INC (US) | 2021-03-18 | — | — | US | claimed |
| US-20170211062-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | claimed |
| US-20160002624-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | claimed |
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS INC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190316123-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-10174318-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170211062-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160002624-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-5009994-A | Uniform distribution | EM DIAGNOSTIC SYSTEMS, INC. (US) | 1991-04-23 | — | — | US | disclosed |
| US-4820627-A | SPRAYING AQUEOUS SOLUTIONS OF LABILE BIOCHEMICALS ONTO BULKING AGENTS | EM DIAGNOSTIC SYSTEMS, INC. (US) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | UPF1, SNRPA1, HNRNPA1 | F7 2147/4885F3 3408/4885SARM1 4841/4885 |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | UPF1, SNRPA1, HNRNPA1 | F7 2147/4885F3 3408/4885SARM1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.